Terrance McGuire - Pulmatrix Insider

Pulmatrix Inc -- USA Stock  

USD 1.51  0.05  3.21%

Director

Mr. Terrance G. McGuire is Independent Director of the Company. Mr. McGuire was previously a director of Pulmatrix Operating from May 2006 until the date of the Merger. Mr. McGuire cofounded Polaris Partners in 1996 and is currently one of their General Partners. Prior to starting Polaris Partners, Mr. McGuire spent seven years at Burr, Egan, Deleage Co., investing in early stage medical and information technology companies. He currently serves on the board of directors of two public companies Acceleron Pharma Inc. and Ironwood Pharmaceuticals Inc. Mr. McGuire also serves on the boards of several private companies, including Adimab, Alector, Quantum Designs, Inc., Arsenal Medical480 Biomedical, Iora Health and MicroCHIPS. Mr. McGuire has formerly served on the board of directors of Editas, Life Line Screening, NextCode, Trevena and Saga, among others. Mr. McGuire is the former chairman of the National VC Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School
Age: 60  Director Since 2015  MBA    
781-357-2333  http://www.pulmatrix.com
McGuire earned a B.S. in physics and economics from Hobart College, an M.S. in engineering from The Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.

Terrance McGuire Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (48.95) % which means that it has lost $48.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (154.45) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.9 M in liabilities with Debt to Equity (D/E) ratio of 30.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.14 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 18 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Pulmatrix Inc to your portfolio

Top Management

Pulmatrix Inc Leadership Team
Terrance McGuire, Director, MBA
Matthew Sherman, Director
Alexander Klibanov, Founder
David Hava, Executive, Ph.D
Akihisa Akao, Director
James Roach, Executive, Ph.D
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
David Maki, Director
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
Hojabr Alimi, Chairman
Prof Edwards, Founder
David JD, Executive

Stock Performance

Pulmatrix Performance Indicators